LARG Inhibitors

The chemical class of LARG inhibitors includes a range of compounds that can indirectly modulate the activity of LARG by targeting various signaling pathways associated with Rho GTPases and cell signaling. These inhibitors work through diverse mechanisms, impacting LARG activity by altering the signaling elements upstream or downstream of pathways in which LARG is involved. Compounds like Y-27632, CCG-1423, and Rhosin exemplify this class by inhibiting LARG through their effects on Rho-kinase, Rho/MKL1/SRF transcriptional activity, and Rho GTPase activity. Inhibitors like NSC23766 and ML141 may inhibit LARG indirectly by disrupting Rac1 and Cdc42 signaling pathways, where LARG could play a regulatory role.

Other notable compounds in this class include statins (e.g., Lovastatin), GGTI-298, and CID-1067700, each influencing different aspects of GTPase signaling and post-translational modifications. By modulating these processes, these inhibitors can indirectly affect LARG's function in cell signaling and regulation. Additionally, compounds like Tozasertib, BMS-5, and Fasudil demonstrate the ability to inhibit LARG through their effects on Aurora kinase, LIM kinase, and Rho-kinase pathways. In summary, the LARG inhibitors class encompasses compounds with diverse mechanisms of action, all converging on the modulation of cell signaling pathways involving Rho GTPases. By targeting upstream elements of these pathways or indirectly influencing LARG activity through pathway interactions and signaling cross-talk.